Kolkata, 17 February 2026:
Zydus Lifesciences Limited has announced the launch of PEPAIR™, described as India’s first affordable Oscillating Positive Expiratory Pressure (OPEP) device, aimed at improving respiratory health through a drug-free, handheld solution. The device is designed to assist patients suffering from chronic respiratory conditions such as COPD, asthma, and bronchiectasis by supporting effective mucus clearance and easing breathing.
Developed with a 3-resistance system, PEPAIR™ helps loosen congestion, open airways, and enhance mucociliary clearance. The company estimates that over 90 lakh patients in India live with chronic respiratory diseases where persistent mucus hypersecretion remains a major clinical challenge requiring daily airway-clearance support.
The launch comes through a strategic agreement with AeroDel Technology Innovations Pvt. Ltd., a medical device firm focused on pulmonary drug-delivery and rehabilitation technologies. In a patient-centric move to bridge affordability gaps, the device has been priced at ₹990 per unit, making OPEP therapy more accessible to a wider population.
Speaking on the development, Sharvil Patel, Managing Director of Zydus Lifesciences Limited, said the innovation reflects the company’s commitment to accessible healthcare:
“With PEPAIR™, India’s first affordable OPEP device, we are introducing a drug-free, handheld solution designed to support better breathing for patients with COPD, asthma and bronchiectasis.”
OPEP therapy uses a handheld device that generates positive pressure and oscillations during exhalation, helping dislodge mucus, reduce airway obstruction, and improve therapeutic outcomes. Though recommended in clinical practice guidelines, access has historically been limited due to cost barriers — a gap PEPAIR™ aims to address.
The launch also comes amid a sharp rise in respiratory illnesses in India, driven by worsening air pollution, climate-linked allergens, rapid urbanisation, and delayed diagnosis of chronic lung diseases.
Zydus, a major player in India’s respiratory therapy segment, continues to expand its portfolio across oral bronchodilators and advanced inhalation therapies, reinforcing its focus on innovative pulmonary care solutions.
